Wan Xiaoyu, Yap Jiajun, Chen Junjun, Li Yifan, Faruk Regina, Tan Nazereth Chor Boon, Ma Yiying, Lim Yiting, Jubri Karlina Bte, Hu Jingyi, Yuan Jimin, Zhang Ge, Li Quan, Yap Yoon Sim, Lam Paula, Wang Mei, Fu Nai Yang, Hu Jiancheng
The Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore General Hospital, 30 Hospital Boulevard, Singapore 168583.
The Cancer and Stem Cell Program, Duke-NUS Medical School, 8 College Road, Singapore 169857.
Theranostics. 2025 Jan 6;15(5):2035-2051. doi: 10.7150/thno.103958. eCollection 2025.
The Ser/Thr kinase RAF, particularly BRAF isoform is a dominant target of oncogenic mutations and many mutations have been identified in various cancers. However, how these mutations except V600E evade the regulatory machinery of RAF protein and hence trigger its oncogenicity remains unclear. In this study, we used mutagenesis, peptide affinity assay, immunoprecipitation, immunoblot, and complementary split luciferase assay as well as mouse xenograft tumour model to investigate how the function of RAF is cooperatively regulated by Cdc37/Hsp90 chaperones and 14-3-3 scaffolds and how this regulatory machinery is evaded by prevalent non-V600 mutations. We found that Cdc37/Hsp90 chaperones engaged with mature BRAF proteins promoted together with 14-3-3 scaffolds a switch of BRAF proteins from active open dimers into inactive close monomers. Most non-V600 mutations were enriched on or around the Cdc37/Hsp90-binding segments of BRAF, which impair association of CDc37/Hsp90 chaperones with BRAF and hence trap BRAF in active open conformation favouring dimerization. These BRAF mutants with high dimer propensity sustained a prolonged ERK signaling, and were effectively targeted by RAF dimer breaker plx8394 and . In contrast, CRAF and ARAF existed as immature monomers highly packaged with Cdc37/Hsp90 chaperones, which will be released upon dimerization driven by RAS-GTP binding with their N-terminus as well as 14-3-3 scaffold association with their C-terminus. Mature CRAF and ARAF dimers also sustained a prolonged ERK signaling as non-V600 BRAF mutants by virtue of absence of the C-terminal Cdc37/Hsp90-binding segment. Cdc37/Hsp90 chaperones and 14-3-3 scaffolds cooperatively facilitate the switch of RAF proteins from open active dimers to close inactive monomers. Non-V600 mutations disrupt this regulatory machinery, and trap RAF in dimers, which could be targeted by RAF dimer breakers.
丝氨酸/苏氨酸激酶RAF,尤其是BRAF亚型,是致癌突变的主要靶点,并且在各种癌症中已鉴定出许多突变。然而,除V600E之外的这些突变如何逃避RAF蛋白的调节机制并因此引发其致癌性仍不清楚。在本研究中,我们使用诱变、肽亲和测定、免疫沉淀、免疫印迹、互补分裂荧光素酶测定以及小鼠异种移植肿瘤模型,来研究RAF的功能如何由Cdc37/Hsp90伴侣蛋白和14-3-3支架蛋白协同调节,以及这种调节机制如何被常见的非V600突变所逃避。我们发现,与成熟BRAF蛋白结合的Cdc37/Hsp90伴侣蛋白与14-3-3支架蛋白一起促进BRAF蛋白从活性开放二聚体转变为无活性紧密单体。大多数非V600突变富集在BRAF的Cdc37/Hsp90结合区段上或其周围,这损害了Cdc37/Hsp90伴侣蛋白与BRAF的结合,从而使BRAF处于有利于二聚化的活性开放构象中。这些具有高二聚化倾向的BRAF突变体维持了延长的ERK信号传导,并且被RAF二聚体破坏剂plx8394有效靶向。相比之下,CRAF和ARAF以与Cdc37/Hsp90伴侣蛋白高度结合的未成熟单体形式存在,它们将在RAS-GTP与其N端结合以及14-3-3支架蛋白与其C端结合驱动的二聚化过程中释放。成熟的CRAF和ARAF二聚体由于缺乏C端Cdc37/Hsp90结合区段,也像非V600 BRAF突变体一样维持了延长的ERK信号传导。Cdc37/Hsp90伴侣蛋白和14-3-3支架蛋白协同促进RAF蛋白从开放活性二聚体向紧密无活性单体的转变。非V600突变破坏了这种调节机制,并使RAF被困在二聚体中,而RAF二聚体破坏剂可以靶向这些二聚体。